Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis.

Next Previous
X
Search
Trial Profile

A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dirucotide (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms MAESTRO-03

    • Most Recent Events

    • 18 Aug 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 27 Jul 2009 Status changed from recruiting to discontinued based on results of the MAESTRO-01 trial (see trial profile 700008236), according to an Eli Lilly media release.
    • 07 Jul 2009 Planned end date changed from 1 Jun 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top